Investors
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 12, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
May 11, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device,...
-
May 9, 2022Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard® DNA test to over 8 million covered lives
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
Apr 28, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a...
-
Apr 25, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Apr 4, 2022Updated American College of Gastroenterology clinical guideline supports esophageal precancer screening with EsoGuard® on samples collected with EsoCheck®
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
-
Mar 30, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 28, 2022Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary...
-
Mar 24, 2022Cleveland VA enrolls first patient in DoD-funded study of EsoGuard’s impact in improving efficiency and cost-effectiveness of early detection of esophageal precancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 23, 2022Patients in Seattle, Portland, and Boise metropolitan areas now have access to a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 7, 2022Company conference call and webcast at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc....
-
Mar 4, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Mar 3, 2022New wholly owned Lucid subsidiary now performing EsoGuard® Esophageal DNA Test in its own new state-of-the-art CLIA-certified, CAP-accredited clinical laboratory
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Feb 10, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Jan 12, 2022
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc....
-
Jan 6, 2022
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Dec 1, 2021Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer before it progresses to deadly cancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Nov 17, 2021
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Nov 16, 2021Conference call to be held today at 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its majority-owned subsidiary...
-
Nov 11, 2021Patients in Denver, Salt Lake City, and Las Vegas metropolitan areas now have access to a rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....
-
Nov 3, 2021Company conference call and webcast at 4:30PM EDT
NEW YORK--(BUSINESS WIRE)-- PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc....
-
Oct 28, 2021BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Oct 21, 2021
NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
Oct 21, 2021NEW YORK--(BUSINESS WIRE)-- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
Oct 18, 2021NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc....
- Oct 13, 2021
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc....